While genetic and pharmacological inhibition of GR did not alter cancer cell proliferation and MEK-ERK activation, GR inhibition significantly decreased cell viability and MEK-ERK activity when the cells were treated with a sublethal dose of cisplatin (Fig. 5a, b; Supplementary Fig. 5a, b). The gene discussed is NR3C1; the disease is cancer.